NASDAQ:OTLK Oncobiologics (OTLK) Stock Price, News & Analysis $0.73 -0.01 (-1.35%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$0.72 -0.01 (-1.37%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oncobiologics Stock (NASDAQ:OTLK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oncobiologics alerts:Sign Up Key Stats Today's Range$0.68▼$0.8250-Day Range$0.20▼$0.7452-Week Range$0.16▼$3.39Volume31.42 million shsAverage Volume31.33 million shsMarket Capitalization$88.23 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingHold Company Overview Oncobiologics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation. Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary. This global footprint enables the company to conduct end-to-end process development and scale-up operations, optimizing both development timelines and production costs in major biopharmaceutical markets. The company’s pipeline comprises multiple biosimilar candidates targeting established therapies in oncology and supportive care, with programs at various stages of preclinical and clinical development. Oncobiologics advances its portfolio through a disciplined clinical strategy and selective partnerships designed to streamline regulatory pathways. By focusing on broadening patient access to proven biologic medicines, the company seeks to address unmet needs in the United States, Europe and other global regions with its upcoming biosimilar products.AI Generated. May Contain Errors. Read More Oncobiologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreOTLK MarketRank™: Oncobiologics scored higher than 51% of companies evaluated by MarketBeat, and ranked 571st out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingOncobiologics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 5 hold ratings, and 1 sell rating.Upside PotentialOncobiologics has a consensus price target of $4.50, representing about 516.4% upside from its current price of $0.73.Amount of Analyst CoverageOncobiologics has only been the subject of 3 research reports in the past 90 days.Read more about Oncobiologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oncobiologics are expected to grow in the coming year, from ($0.51) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncobiologics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncobiologics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Oncobiologics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.74% of the float of Oncobiologics has been sold short.Short Interest Ratio / Days to CoverOncobiologics has a short interest ratio ("days to cover") of 2.19, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncobiologics has recently increased by 41.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncobiologics does not currently pay a dividend.Dividend GrowthOncobiologics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.72 News SentimentOncobiologics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Oncobiologics this week, compared to 2 articles on an average week.Search Interest15 people have searched for OTLK on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows8 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncobiologics insiders have not sold or bought any company stock.Percentage Held by Insiders2.80% of the stock of Oncobiologics is held by insiders.Percentage Held by Institutions11.20% of the stock of Oncobiologics is held by institutions.Read more about Oncobiologics' insider trading history. Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OTLK Stock News HeadlinesOncobiologics (NASDAQ:OTLK) Rating Increased to Sell at Wall Street ZenMay 30 at 1:20 AM | americanbankingnews.comOutlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28 at 4:00 PM | globenewswire.comMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.May 30 at 1:00 AM | Behind the Markets (Ad)Outlook Shares Jump Following FDA Appeal Decision For LYTENAVAMay 26, 2026 | benzinga.comOutlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)May 26, 2026 | globenewswire.comOutlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comOutlook Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingApril 23, 2026 | globenewswire.comOutlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 22, 2026 | globenewswire.comSee More Headlines OTLK Stock Analysis - Frequently Asked Questions How have OTLK shares performed this year? Oncobiologics' stock was trading at $1.58 at the beginning of the year. Since then, OTLK shares have decreased by 53.8% and is now trading at $0.73. How were Oncobiologics' earnings last quarter? Oncobiologics, Inc. (NASDAQ:OTLK) announced its quarterly earnings results on Friday, May, 15th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.04. The firm earned $0.13 million during the quarter, compared to the consensus estimate of $4.39 million. When did Oncobiologics' stock split? Oncobiologics shares reverse split on the morning of Thursday, March 14th 2024.The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Oncobiologics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncobiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings5/15/2026Today5/30/2026Next Earnings (Estimated)8/13/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 4 days ago, OTLK's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OTLK CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees20Year Founded2011Price Target and Rating Average Price Target for Oncobiologics$4.50 High Price Target$6.00 Low Price Target$3.00 Potential Upside/Downside+516.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.42 million Net MarginsN/A Pretax Margin-18,772.37% Return on EquityN/A Return on Assets-291.28% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.45 Sales & Book Value Annual Sales$333.14 thousand Price / Sales264.84 Cash FlowN/A Price / Cash FlowN/A Book Value($0.24) per share Price / Book-3.04Miscellaneous Outstanding Shares120,863,000Free Float117,479,000Market Cap$88.23 million OptionableOptionable Beta0.32 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:OTLK) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredWhen SpaceX goes public your retirement pays the priceWhen SpaceX files its S-1, institutions will liquidate holdings, rebalance portfolios, and free up capital for...Reagan Gold Group | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
